[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Hori J, Kato Y, Iwata T, Taniguchi N, Hashimoto H, Yachiku S: [A case of penile malignant melanoma]. Hinyokika Kiyo; 2003 Aug;49(8):493-6
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inguinal lymph nodes were palpable bilaterally.
  • Clinical diagnosis was penile malignant melanoma.
  • Cystoscopy and urethrography revealed urethral invasion of malignant melanoma, and magnetic resonance imaging (MRI) of the penis revealed invasion to prostate, and pelvic lymph node metastases in abdominal compuled tomography (CT) but no organ metastases.
  • Total cystectomy, total penectomy, bilateral inguinal and pelvic lymph node dissection and bilateral ureterocutaneostomy were performed in February, 2002.
  • After these therapies, chemotherapy was performed.
  • Five months later, CT revealed multiple lung and brain metastases, and radiation therapy and chemotherapy were performed.
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518390.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


2. Yotsumoto M, Ichikawa N, Ueno M, Higuchi Y, Asano N, Kobayashi H: CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient. Intern Med; 2009;48(7):559-62
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was diagnosed with diffuse large B cell lymphoma (DLBCL) by a biopsy of the inguinal lymph node.
  • IgH/MYC translocation was detected by in situ hybridization of the lymph node and chromosomal analysis of bone marrow cells showed 46, XY, t(8 ; 14)(q24 ; q32)add(14)(q32), der(21)t(1 ; 21)(q12 ; p11).
  • He showed a transient response to multi-agent chemotherapy, and during the course of salvage chemotherapy, he died of urinary infection.
  • [MeSH-major] Antigens, Neoplasm / analysis. Genes, myc. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Syndecan-1 / analysis. Translocation, Genetic
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cytomegalovirus Retinitis / complications. Cytomegalovirus Retinitis / drug therapy. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / diagnosis. Fatal Outcome. Ganciclovir / therapeutic use. Humans. Lymph Nodes / pathology. Male. Middle Aged. Salvage Therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Urinary Tract Infections / complications. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336959.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; P9G3CKZ4P5 / Ganciclovir; VAD I protocol
  •  go-up   go-down


3. Heidenreich A, Jakse G: [Neoadjuvant and adjuvant chemotherapy in patients with advanced penile cancer]. Urologe A; 2007 Oct;46(10):1395-6, 1398-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant and adjuvant chemotherapy in patients with advanced penile cancer].
  • [Transliterated title] Neoadjuvante und adjuvante Chemotherapie bei Patienten mit fortgeschrittenem Peniskarzinom.
  • At the time of initial diagnosis up to 45% of the patients already demonstrate metastatic disease and need some type of systemic treatment.
  • It is the aim of this paper to review the current concepts of adjuvant and neoadjuvant chemotherapy for locally advanced penile cancer.
  • A curative effect of combined surgical and cytotoxic management can only be achieved in patients with locoregional spread to the lymph nodes, but not with systemic spread.
  • Although there are prospective randomized trials available indicating the optimal cytotoxic regime, cisplatin-based protocols or combination therapies with bleomycin, vincristine, and methotrexate appear to be the most effective options.
  • Finally, there are no data available with regard to the effect of adjuvant chemotherapy on progression-free survival.
  • In patients with locoregional bulky disease or with fixed inguinal lymph nodes, neoadjuvant chemotherapy will result in a partial response in 20-60% of patients and enables complete resection of the mass.
  • For the future, the use of taxane-based chemotherapy as described for squamous cell cancer of other origin might improve outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Penile Neoplasms / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Lymph Node Excision. Lymphatic Metastasis / pathology. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Neoplasm Staging. Penis / pathology. Penis / surgery. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Int. 1999;62(4):245-8 [10567893.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):433-8 [2297633.001]
  • [Cites] Urol Oncol. 2003 Nov-Dec;21(6):431-8 [14693269.001]
  • [Cites] Urol Int. 1999;62(4):238-44 [10567892.001]
  • [Cites] Urology. 1993 Nov;42(5):559-62 [7694417.001]
  • [Cites] BJU Int. 2004 Dec;94(9):1248-52 [15610099.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):1-8 [15183542.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] Arch Ital Urol Androl. 1996 Jun;68(3):169-72 [8767505.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1089-98 [9426328.001]
  • [Cites] Acta Oncol. 1988;27(6b):823-4 [2466471.001]
  • [Cites] J Urol. 2007 Apr;177(4):1335-8 [17382727.001]
  • [Cites] Urologe A. 2005 Jun;44(6):657-61 [15891865.001]
  • [Cites] J Urol. 1992 Mar;147(3):630-2 [1538445.001]
  • [Cites] J Urol. 1998 Nov;160(5):1770-4 [9783949.001]
  • [Cites] Urology. 2004 Apr;63(4):778-80 [15072904.001]
  • [Cites] Urologe A. 2003 Nov;42(11):1466-9 [14624345.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] J Urol. 1994 Oct;152(4):1124-6 [8072080.001]
  • [Cites] Cancer Invest. 2003;21(1):41-6 [12643008.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):240-7 [15050955.001]
  • [Cites] J Urol. 2007 Mar;177(3):947-52; discussion 952 [17296384.001]
  • [Cites] J Urol. 1991 Nov;146(5):1284-7 [1719241.001]
  • [Cites] BJU Int. 2006 Dec;98(6):1225-7 [17125480.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1637-42 [11104558.001]
  • [Cites] Head Neck. 2007 Apr;29(4):315-24 [17252600.001]
  • (PMID = 17846739.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; TIP regimen
  •  go-up   go-down


Advertisement
4. Olnes MJ, Nicol T, Duncan M, Bohlman M, Erlich R: Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy. Leuk Lymphoma; 2002 Apr;43(4):817-21
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.
  • Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature.
  • Patients with this malignancy have been treated with chemotherapy regimens used against non-Hodgkin's lymphomas.
  • In this article we describe a case of IDCS occurring in a 44 year old female who presented with abdominal pain and inguinal adenopathy.
  • Staging of the tumor with CT scan, PET scan, and bone marrow biopsy demonstrated inguinal and abdominal lymphadenopathies, a large mass encasing the small bowel, and extensive liver infiltration.
  • Morphologic and cytochemical analysis of biopsies from the abdominal mass and inguinal node were consistent with a diagnosis of IDCS, and immunohistochemical stains of the lymph node were positive for CLA, Kp-1, S-100, while negative for CD1a, CD3, CD20, CKER, and HMB45.
  • Treatment of this patient with ABVD chemotherapy resulted in rapid clinical improvement with a marked decrease in tumor burden after two cycles of ABVD, and a complete response after six cycles of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dendritic Cells / pathology. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymph Nodes / pathology. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153170.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


5. Blanchard P, Plantade A, Pagès C, Afchain P, Louvet C, Tournigand C, de Gramont A: Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol; 2007 Jan;104(1):41-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
  • Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy.
  • After initial optimal treatment, median progression-free survival (PFS) was 26 months.
  • Sites of relapse were retroperitoneum (n=15), left supraclavicular (n=7), mediastinum (n=4), iliac (n=4) and inguinal (n=3).
  • Treatment modalities were surgery in eight patients (30%), chemotherapy in 15 (55%) and radiotherapy in 5 patients (18%), alone or in combination.
  • Median OS from initial diagnosis was 68 months.
  • Time to relapse may not have its usual prognostic value.
  • Immediate or delayed therapy should be discussed in case of asymptomatic ILNR.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952391.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Fukada T, Yasuno K, Koyama T, Tanaka H, Seike K, Kametaka H, Hayashi T, Hashimoto R, Kawano H, Hasegawa A: [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1665-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
  • A 53-year-old man, admitted for inguinal hernia, complained of body weight loss in a preoperative condition check.
  • After that his general condition recovered, and two cycles of neoadjuvant chemotherapy (NAC) by irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) therapy were performed on an outpatient basis.
  • We established a diagnosis of down staging for stage IIIa, and performed a lower anterior resection with D 2 lymph node dissection to allow a curability-A resection.
  • Post-operatively, two cycles of IFL therapy were then performed.
  • There has been no sign of recurrence, and no adverse effects by chemotherapy have been seen during this treatment.
  • Thus, NAC by IFL therapy can be one of the useful treatment approaches for patients with advanced rectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Rectal Neoplasms / drug therapy. Rectal Neoplasms / surgery
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Colostomy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Ileus / etiology. Ileus / surgery. Leucovorin / administration & dosage. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108739.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Mistrangelo M, Pelosi E, Bellò M, Castellano I, Cassoni P, Ricardi U, Munoz F, Racca P, Contu V, Beltramo G, Morino M, Mussa A: Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):73-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer.
  • BACKGROUND: Inguinal lymph node metastases in patients with anal cancer are an independent prognostic factor for local failure and overall mortality.
  • Inguinal lymph node status can be adequately assessed with sentinel node biopsy, and the radiotherapy strategy can subsequently be changed.
  • We compared this technique vs. dedicated 18F-fluorodeoxyglucose positron emission tomography (PET) to determine which was the better tool for staging inguinal lymph nodes.
  • METHODS AND MATERIALS: In our department, 27 patients (9 men and 18 women) underwent both inguinal sentinel node biopsy and PET-CT.
  • PET-CT was performed before treatment and then at 1 and 3 months after treatment.
  • RESULTS: PET-CT scans detected no inguinal metastases in 20 of 27 patients and metastases in the remaining 7.
  • Histologic analysis of the sentinel lymph node detected metastases in only three patients (four PET-CT false positives).
  • None of the patients negative at sentinel node biopsy developed metastases during the follow-up period.
  • CONCLUSIONS: In this series of patients with anal cancer, inguinal sentinel node biopsy was superior to PET-CT for staging inguinal lymph nodes.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / radionuclide imaging. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Positron-Emission Tomography / methods. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy / methods. False Positive Reactions. Female. Fluorodeoxyglucose F18. Humans. Inguinal Canal. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging / methods. Radiopharmaceuticals. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632066.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Preis E, Jakse G: [The significance of inguinal lymphadenectomy in carcinoma of the penis]. Urologe A; 2006 Sep;45 Suppl 4:176-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The significance of inguinal lymphadenectomy in carcinoma of the penis].
  • The occurrence of inguinal lymph node metastases from squamous cell carcinoma of the penis depends on local tumor extension, tumor grade, and vascular invasion.
  • Whilst imaging techniques and fine needle biopsy can detect metastases to the inguinal nodes, resection of the superficial inguinal nodes remains the procedure of choice for diagnosis.
  • The risk profile defined in the guidelines of the EAU is used to decide whether modified inguinal lymphadenectomy is indicated in the case of nonpalpable lymph nodes.
  • Resection of the sentinel lymph node marked by (99)Tc and dye has not yet been adequately evaluated as an alternative to be accepted as the standard method.When the superficial inguinal lymph nodes are found to harbor metastases the next step is a radical bilateral inguinal lymphadenectomy.
  • When metastases are found in two lymph nodes or extranodal tumor growth is observed, or imaging techniques reveal enlarged nodes in the pelvis the lymphadenectomy is extended to the pelvic nodes.
  • Chemotherapy and radiotherapy and the two combined have not been tested for efficacy, but are used individually before and after surgery, depending on the local tumor extent.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymph Node Excision / methods. Penile Neoplasms / surgery
  • [MeSH-minor] Germany. Humans. Inguinal Canal. Lymphatic Metastasis / pathology. Male. Neoplasm Invasiveness. Neoplasm Staging. Penis / pathology. Postoperative Complications / etiology. Practice Guidelines as Topic. Prognosis. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Surg Oncol. 1990;6(4):241-2 [2389105.001]
  • [Cites] J Urol. 1987 May;137(5):880-2 [3573181.001]
  • [Cites] J Urol. 1986 Jul;136(1):38-41 [3712610.001]
  • [Cites] Eur Urol. 2005 May;47(5):601-6; discussion 606 [15826750.001]
  • [Cites] Urol Oncol. 2004 May-Jun;22(3):236-44; discussion 244-5 [15271324.001]
  • [Cites] J Urol. 1995 Dec;154(6):1999-2003 [7500444.001]
  • [Cites] J Urol. 1994 May;151(5):1239-43 [8158767.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] J Urol. 2004 Aug;172(2):494-7 [15247712.001]
  • [Cites] Br J Urol. 1994 Nov;74(5):646-51 [7530129.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] Int Urol Nephrol. 2002;34(2):245-50 [12775105.001]
  • [Cites] J Urol. 2003 Sep;170(3):783-6 [12913697.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):247-56 [1574815.001]
  • [Cites] Arch Ital Urol Androl. 1996 Jun;68(3):169-72 [8767505.001]
  • [Cites] BJU Int. 2001 Sep;88(5):473-83 [11589660.001]
  • [Cites] Acta Chir Scand. 1958 May 23;115(1-2):25-45 [13558905.001]
  • [Cites] J Urol. 1998 Nov;160(5):1770-4 [9783949.001]
  • [Cites] Eur Urol. 1994;26(2):123-8 [7957466.001]
  • [Cites] Cancer. 1955 Mar-Apr;8(2):371-8 [14352176.001]
  • [Cites] BJU Int. 2006 Jul;98(1):70-3 [16831146.001]
  • [Cites] J Urol. 2005 Sep;174(3):923-7; discussion 927 [16093989.001]
  • [Cites] Eur Urol. 1997;32(1):5-15 [9266225.001]
  • [Cites] BJU Int. 2000 Oct;86(6):690-3 [11069378.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):453-7 [9523669.001]
  • [Cites] J Urol. 2001 May;165(5):1633-4 [11342941.001]
  • [Cites] Br J Urol. 1965 Apr;37:211-22 [14282085.001]
  • [Cites] Urologe A. 2001 Jul;40(4):308-12 [11490865.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1225-8 [16686716.001]
  • [Cites] J Urol. 2002 Apr;167(4):1638-42 [11912379.001]
  • [Cites] J Urol. 2003 Apr;169(4):1349-52 [12629358.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):267-76 [1574817.001]
  • [Cites] J Urol. 2001 Apr;165(4):1138-42 [11257655.001]
  • [Cites] Onkologie. 2005 Mar;28(3):135-8 [15772463.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):963-8 [11598165.001]
  • [Cites] Eur Urol. 2002 Sep;42(3):199-203 [12234502.001]
  • (PMID = 16933120.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


9. Takeshita H, Yonese J, Fujii Y, Kawakami S, Komai Y, Ohkubo Y, Yamamoto S, Ishikawa Y, Seto Y, Ohyama S, Fukui I: Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor. Int J Clin Oncol; 2007 Dec;12(6):485-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor.
  • A 34 year-old man with a diagnosis of nonseminomatous testicular cancer with retroperitoneal lymph node metastasis (T1N3M0S2, stage IIIb; intermediate prognosis, made after right inguinal orchiectomy was performed) was referred to our hospital after having had a total of eight courses of systemic chemotherapy and external-beam radiotherapy to the retroperitoneal region in the previous 1 year.
  • Two courses of paclitaxel, etoposide, and cisplatin combined chemotherapy (TEP; paclitaxel 120 mg/m(2) day 1, etoposide 80 mg/m(2) days 2-5, cisplatin 20 mg/m(2) days 2-5) failed to normalize the AFP level.
  • During the following 2 years he underwent salvage surgery four times; infrarenal retroperitoneal lymph node dissection (RPLND), left neck lymph node dissection, thoracic duct excision, and suprarenal RPLND.
  • Viable cancer cells were found in all surgically resected specimens, except for the neck lymph node specimen.
  • The present case suggests that repeated salvage surgery may be beneficial in selected patients with a chemotherapy-resistant metastatic germ cell tumor.
  • [MeSH-minor] Adult. Antinematodal Agents / therapeutic use. Drug Resistance, Neoplasm. Humans. Lymphatic Metastasis. Male. Remission Induction. Reoperation. Salvage Therapy. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Clin Oncol. 2010 Oct;15(5):528-9 [20686911.001]
  • [Cites] J Urol. 2000 Aug;164(2):381-4 [10893590.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1859-63 [11919245.001]
  • [Cites] Cancer. 1992 Nov 1;70(9):2354-7 [1382832.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):324-9 [8381163.001]
  • (PMID = 18071871.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antinematodal Agents; 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


10. Wu YC, Huang SL, Chuang CK, Jung SM, Lai CH: Successful salvage treatment of recurrent endometrial cancer with bulky central tumor and extensive lymph node metastasis. A case report. Eur J Gynaecol Oncol; 2004;25(6):739-41
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful salvage treatment of recurrent endometrial cancer with bulky central tumor and extensive lymph node metastasis. A case report.
  • A 55-year-old endometrial adenocarcinoma patient with bulky central recurrences and pelvic and inguinal lymph node metastases underwent laparotomy and paraaortic, pelvic and inguinal lymphadenectomy followed by concurrent chemoradiation (with cisplatin) to the paraaortic and inguinal lymph nodes as well as the whole pelvis.
  • Neck and mediastinal lymph node metastasis emerged during treatment.
  • Neck-node radiation and epirubicin was added followed by paclitaxel and carboplatin.
  • Therefore, a multimodality approach with a combination of radical resection (even pelvic exenteration), radiotherapy and chemotherapy could be offered to well-selected patients with recurrent endometrial cancer despite out-of-field progression during therapy and in-field local failure to initial salvage treatment.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged. Salvage Therapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15597856.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Sumiyoshi K, Strebel FR, Rowe RW, Bull JM: The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. Int J Hyperthermia; 2003 Mar-Apr;19(2):103-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases.
  • Many women diagnosed with invasive breast cancer have undetected occult metastases at the time of their primary tumour diagnosis.
  • Therefore, administering an angiogenesis-blocking treatment from the time of diagnosis could reduce the incidence of metastasis and, ultimately, increase patient survival.
  • It is hypothesized that an antiangiogenesis strategy combining fever-range whole-body hyperthermia (FR-WBH) and metronomic chemotherapy could inhibit the development of metastatic disease with minimal toxicity.
  • To test this theory, a low, daily dose of the topoisomerase-I inhibitor irinotecan hydrochloride (CPT-11) was administered over a prolonged period of time to rats bearing the highly metastatic MTLn3 mammary adenocarcinoma primary tumour surgically excised on day 12 after implantation.
  • This systemic hyperthermia enhances chemotherapy-induced cytotoxicity as well as immunological activity.
  • Both the group treated with FR-WBH alone and the combined FR-WBH + CPT-11 group had delayed onset and reduced incidence of axillary lymph node metastases compared to control (p < 0.05).
  • Combination therapy of FR-WBH + CPT-11 resulted in a significantly greater inhibition of axillary lymph node metastasis volume compared to both control and CPT-11 alone (p < 0.02) at day 16.
  • Interestingly, none of the therapies significantly affected inguinal lymph node metastases.
  • Lung metastases were decreased by 36% at the time of death in rats treated with FR-WBH + CPT-11, by 25% in the CPT-11 alone group and by 14% in the FR-WBH alone group.
  • These data suggest that, after excision of the primary tumour, FR-WBH and metronomic CPT-11 can be safely combined to reduce distant lymph node and lung metastases and, thus, to increase survival.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Hyperthermia, Induced. Mammary Neoplasms, Experimental / therapy. Neoplasm Metastasis / therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Female. Rats. Rats, Inbred F344

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12623634.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA43090
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Marconnet L, Bouchot O, Culine S, Avances C, Rigaud J, membres du CCAFU-OGE: [Treatment of lymph nodes in epidermoid carcinoma of the penis: review of literature by the Committee of Cancerology of the French Association of Urology-External Genital Organs Group (CCAFU-OGE)]. Prog Urol; 2010 May;20(5):332-42
Genetic Alliance. consumer health - Epidermoid Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of lymph nodes in epidermoid carcinoma of the penis: review of literature by the Committee of Cancerology of the French Association of Urology-External Genital Organs Group (CCAFU-OGE)].
  • [Transliterated title] Prise en charge ganglionnaire dans le carcinome épidermoïde du pénis: revue de la littérature par le comité de cancérologie de l'Association française d'urologie-groupe organes génitaux externes (CCAFU-OGE).
  • INTRODUCTION: Invasive lymph nodes are an independent factor of prognosis and essential for the survival of patients with cancer of the penis.
  • The aim of this article is to analyse published research results on the diagnosis and treatment of lymph nodes in cancer of the penis.
  • MATERIAL AND METHOD: Bibliographic research on Medline was carried out using the terms penile carcinoma, lymph node dissection, lymphadenectomy, survival, chemotherapy and radiotherapy.
  • RESULTS: The risk of lymph node metastasis depends on the stage of the primitive tumour, its histological grade, the presence of venous and lymphatic embolus and the presence of palpable lymph nodes (classification into risk groups by the European Association of Urology [EAU]).
  • A diagnosis of suspected adenopathy based on clinical examination associated with FNA biopsy is essential.
  • The search for the sentinel lymph node although interesting remains to be defined, especially in patients who have no palpated adenopathy but are at risk of metastasis.
  • Not only is surgery on inguinal lymph nodes the only reliable way of confirming an invasive metastatic lymph node, it also plays a therapeutic and prognostic role for patients who have a tumour of the penis which risks spreading to lymph nodes (intermediate or high risk according to EAU).
  • The type of dissection is in function with the clinical examination: a radical inguinal dissection is recommended in the case of palpated adenopathy and a modified inguinal dissection is recommended if there is no palpated adenopathy, this should be radicalised in the case of metastatic adenopathy on histological examination.
  • Neo-adjuvant or adjuvant chemotherapy would appear to play a interesting role when combined with surgery for certain patients without there being currently being precise consensus because of the lack of documented cases.
  • The same goes for external radiotherapy on inguinal lymph nodes which seems to play a role in local controls of the lymph node disease though increases morbidity risks of surgical intervention.
  • CONCLUSION: Lymph node dissection alone has a therapeutic role in patients who have reached metastasis of lymph nodes (stage pN1).
  • However, it remains insufficient for patients who have metastatic infiltration of more than 2 lymph nodes (stage > or =pN2).
  • Consequently, it would seem important to develop multimodal approaches in the treatment of these patients in order to increase the rate of response to treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymph Node Excision. Penile Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. France. Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Societies, Medical. Urology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20471577.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


13. Bouchot O, Rigaud J: [Diagnosis and treatment of penis cancer]. Presse Med; 2010 Sep;39(9):871-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of penis cancer].
  • [Transliterated title] Diagnostic et traitement du cancer du pénis.
  • Penile cancer is a rare tumor in Europe and is therefore associated with risks of diagnostic delay for stage Ta-T1 tumors or pre-epitheliomatous lesions and of an inadequate treatment strategy.
  • Clinical examination by palpation is essential in primary tumors to look for infiltration in the corpus spongiosum and the tunica albuginea of the corpus cavernosa of the penis, and in the lymphatic drainage areas, in particular in the upper inner quadrant of the inguinal lymph nodes.
  • The work-up must include: a biopsy in the case of diagnostic doubt, lymph node aspiration in the case of palpable adenopathies, and whole-body computed tomography (CT).
  • Treatment of the primary tumor can include partial amputation for tumors infiltrating the corpus cavernosa, or conservative treatment for tumors limited to the glands if the diameter is less than 30 mm, after an initial circumcision.
  • Groups at risk of lymph node metastases have been defined as a function of the pathology results of their primary tumors.
  • In these groups at risk, or in the case of clinical lymph node metastasis, dissection of the lymph node has an important role, permitting 5-year survival rates greater than 80 % when the number of metastatic lymph nodes is ≤ 1-2.
  • In the case of more extensive lymph node spread, a combination of chemotherapy and surgery must be discussed in multidisciplinary meetings, especially for younger patients.
  • [MeSH-major] Penile Neoplasms / diagnosis. Penile Neoplasms / therapy
  • [MeSH-minor] Algorithms. Humans. Male. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20494544.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


14. Subramanian VS, Gilligan T, Klein EA: A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance. Nat Clin Pract Urol; 2008 Apr;5(4):220-3
Genetic Alliance. consumer health - Testicular cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A scrotal ultrasound scan showed a right testicular mass, suspicious for neoplasm.
  • The patient underwent right inguinal orchiectomy and was diagnosed with nonseminomatous germ cell tumor of the right testis, composed of yolk sac tumor, teratoma, and embryonal carcinoma with no evidence of metastatic disease.
  • He opted to remain under surveillance rather than undergo primary chemotherapy or retroperitoneal lymph node dissection for his clinical stage I disease.
  • Serologic relapse at 4 months after orchiectomy was successfully treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy.
  • DIAGNOSIS: A 1.7 cm nodule anterior to the right psoas muscle suspicious for metastatic disease that was seen on CT 16 months after orchiectomy was pathologically confirmed as recurrent mature teratoma in the spermatic cord.
  • Additionally, one of eleven interaortocaval lymph nodes showed evidence of teratoma.
  • MANAGEMENT: Bilateral nerve-sparing retroperitoneal lymph node dissection with complete excision of the right spermatic cord was performed.
  • [MeSH-major] Genital Neoplasms, Male / therapy. Neoplasms, Germ Cell and Embryonal / surgery. Spermatic Cord / pathology. Teratoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Disease Management. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / therapy. Orchiectomy. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268549.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins
  •  go-up   go-down


15. Stroh C, Manger T: [Primary amelanotic anorectal melanoma--a case report]. Zentralbl Chir; 2007 Dec;132(6):560-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Das primäre amelanotische Melanom des Rektums - Ein Fallbericht.
  • Therefore transrectal ultrasound is of major importance in the preoperative staging and postoperative follow-up especially in diagnosis of local recurrence by using the ultrasound-guided, transrectal aspiration.
  • The overall survival time is 10 months after diagnosis.
  • 7 months after a wide local excision of the tumour and interferon therapy in case of the absence of pararectal, inguinal metastases and other metastases the patient developed pararectal metastasis.
  • An abdominoperineal resection and resection of inguinal lymph nodes was performed.
  • Two months later paraaortal lymph nodes were detected.
  • We started chemotherapy with Dacarbazin and with regard of the tumour progress the chemotherapy was changed to Vindesin 25 months after first operation supported by a radiotherapy with 40 Gray.
  • The patient died 36 months after diagnosis.
  • CONCLUSION: The prognosis of primary malignant anorectal melanoma is poor, irrespective of surgical treatment.
  • Chemotherapy, radiotherapy and immunotherapy should be considered in the treatment of anorectal melanoma to influence the overall survival.
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease Progression. Endosonography. Fatal Outcome. Female. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Intestinal Mucosa / ultrasonography. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / ultrasonography. Neoplasm Staging. Palliative Care. Proctoscopy. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098086.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Stewart RJ, Martelli H, Oberlin O, Rey A, Bouvet N, Spicer RD, Godzinski J, Stevens MC, International Society of Pediatric Oncology: Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J Clin Oncol; 2003 Mar 1;21(5):793-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
  • Radical inguinal orchidectomy was recommended, but initial retroperitoneal lymph node dissection was not performed.
  • Disease was staged according to the SIOP tumor-node-metastasis staging system.
  • Treatment was stratified by stage.
  • In the MMT 89 study, males with completely resected tumors at diagnosis received less chemotherapy (vincristine and dactinomycin) than patients in the MMT 84 study (ifosfamide, vincristine, and dactinomycin).
  • RESULTS: Median age at diagnosis was 65 months.
  • OS and EFS were significantly worse for males with tumors greater than 5 cm and for males older than 10 years at diagnosis.
  • Intensified chemotherapy incorporating alkylating agents for this subgroup may be preferred to the use of systematic lymphadenectomy to improve survival while minimizing the burden of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dactinomycin / therapeutic use. Ifosfamide / therapeutic use. Mesenchymoma / drug therapy. Rhabdomyosarcoma / drug therapy. Testicular Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Humans. Infant. Lymph Node Excision. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610176.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide; IVA protocol; SIOP protocol
  •  go-up   go-down


17. Hou JL, Wu LY, Zhang HT, Li N, Yu GZ: [Clinicopathological characteristics of six patients with adenoid cystic carcinoma of the Bartholin gland]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):290-3
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the clinicopathological characteristics and treatment of adenoid cystic carcinoma of the Bartholin gland.
  • Surgery was the primary treatment.
  • Four cases underwent radical vulvectomy with bilateral inguinal lymph node dissection and 1 case underwent wide local excision of the vulva with bilateral inguinal lymph node biopsy.
  • RESULTS: All patients had definite pathological diagnosis.
  • Cribriform arrangement of tubules and gland-like elements and infiltration of perineural spaces were two main microscopic features of this type of tumor.
  • The pathological examination after surgery revealed that two patients had positive surgical margins, one had negative margin, 1 adjacent to the tumor and 1 unknown; 5 cases had negative inguinal lymph nodes and 1 unknown.
  • Recurrence developed in 4 cases including 3 with both local recurrence and lung metastasis, and one had lung metastasis only.
  • CONCLUSION: Adenoid cystic carcinoma of the Bartholin gland is a slow growing but locally very aggressive neoplasm with a high capacity for local recurrence and lung metastasis.
  • Surgery is the most common and useful treatment.
  • Radiation is a choice of treatment for patients with high risk factors after surgery such as positive surgical margin, deep local invasion and infiltration of perineural spaces or for recurrent patients without opportunity of excision.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510082.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Ehara K, Tsutsumi K, Kinoshita Y, Ueno M, Mine S, Udagawa H: [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1375-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
  • The combination chemotherapy with docetaxel/CDDP/5-FU(DCF)for head and neck squamous carcinoma(SCC) has been widely accepted.
  • It seems quite natural that DCF therapy is expected to be equally effective against esophageal SCC because of their histological similarity.
  • In this report, we present a case of unresectable advanced esophageal SCC with multiple liver metastases which showed remarkable regression by DCF therapy, with relatively slight adverse effects.
  • Abdominal CT scan showed multiple liver metastases with para-aortic lymph node involvement.
  • The clinical stage diagnosis was T3N4M1, Stage IVB, obviously non-resectable far-advanced esophageal SCC.
  • Systemic chemotherapy with DCF was started as the initial treatment.
  • The chemotherapy regimen was as follows.
  • Each course was followed by a 23-day drug-free period, and the entire course was repeated every 28 days.
  • Ten cycles of this DCF chemotherapy were carried out.
  • After 8 cycles, the liver metastases were judged as CR and para-aortic lymph nodes showed a partial response(PR)by CT scan.
  • Until this writing, we added 2 more cycles of DCF therapy for the recurrent para-aortic and inguinal lymph node metastasis.
  • We conclude that DCF therapy is potentially very effective for advanced esophageal SCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Fluorouracil / therapeutic use. Liver Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Esophagoscopes. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed


19. Ye YL, Qin ZK, Zhou FJ, Han H, Liu ZW, Yu SL, Li YH, Chen ZF: [Clinical analysis of stage I pediatric testicular yolk sac tumors: a report of ten cases]. Ai Zheng; 2008 Nov;27(11):1226-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: At present, pediatric testicular yolk sac tumor is hard to be diagnosed at early stage, and the treatment strategy for this disease after radical inguinal orchiectomy is uncertain.
  • Radical inguinal orchiectomy (RIO) was performed for all patients whereas chemotherapy was not administered preoperatively.
  • Pathology examination was used to confirm the diagnosis of yolk sac tumor.
  • One patient with vascular invasion and another one with bilateral testicular yolk sac tumor received cisplatin-based adjuvant chemotherapy.
  • Retroperitoneal lymph node dissection (RPLND) was not performed in these patients.
  • The patient with bilateral testicular tumor had retroperitoneal and lung metastases at 23 months after adjuvant chemotherapy, and achieved complete remission again after salvage chemotherapy.
  • Chemotherapy is recommended to treat patients with high-risk of relapse.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Chemotherapy, Adjuvant. Child, Preschool. Cisplatin / therapeutic use. Etoposide / therapeutic use. Follow-Up Studies. Humans. Infant. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Neoplasm Staging. Orchiectomy / methods. Remission Induction. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / secondary. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000459.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


20. Fernández Gómez JM, Escaf Barmadah S, Guate Ortiz JL, Martín Huescar A, Fresno Forcelledo F, García Rodríguez J, Rodríguez Faba O, Jalón Monzón A, Rodríguez Martínez JJ: [Urologic treatment of testicular germ cell cancer]. Arch Esp Urol; 2002 Oct;55(8):927-36
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urologic treatment of testicular germ cell cancer].
  • [Transliterated title] Tratamiento urológico del cáncer germinal de testículo.
  • OBJECTIVE: To review the treatment of testicular germ-cell cancer in our series.
  • METHODS: 73 cases with the diagnosis of germ-cell testicular tumours were reviewed.
  • We reviewed the treatment options employed in our series, analysing different currently recognised risk factors.
  • Inguinal orchiectomy was performed in all cases except 5 patients in whom tumours were incidentally diagnosed (atrophic testis orchiectomy, hydrocelectomy, trauma) and underwent ipsilateral scrotal excision in a second time.
  • 30 patients received chemotherapy after orchiectomy: 3 metastatic seminomas (stage II) (8.8% of seminomas treated with chemotherapy) and 27 non seminomatous tumours (69.2% of them).
  • Median time to relapse was 4 months (2-102).
  • Orchiectomy is the primary treatment and allows determination of the dissemination risk.
  • Radiotherapy is very effective for localised seminomas with poor prognostic factors, and for non seminomas 2 cycles of chemotherapy seem to be an effective approach, as well as of little toxicity.
  • We must know and apply optimised programs for observation of these tumours (stage I), and also use follow-up protocols after chemotherapy or radiotherapy.
  • Some cases need complex surgery for residual masses resection or post chemotherapy salvage surgery in disseminated tumours (Stages II & III).
  • Sterility treatment protocols are applied to preserve fertility.
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / secondary. Seminoma / drug therapy. Seminoma / pathology. Seminoma / radiotherapy. Seminoma / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12455283.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


21. Cormio G, Loizzi V, Carriero C, Cazzolla A, Putignano G, Selvaggi L: Groin recurrence in carcinoma of the vulva: management and outcome. Eur J Cancer Care (Engl); 2010 May;19(3):302-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Groin recurrence in carcinoma of the vulva: management and outcome.
  • The aim of the study was to investigate the management and outcome of inguinal recurrence in vulvar carcinoma patients.
  • Twenty-one patients were found to have groin recurrence.
  • Median interval between primary treatment of vulvar cancer and groin recurrence was 7 months.
  • Three patients refused any treatment, 3 received chemotherapy, 2 inguino-pelvic radiotherapy and 13 had resection of the groin recurrence.
  • After surgery seven patients received irradiation of the groin and pelvis, and three patients received chemotherapy.
  • One patient died following surgery; 19 patients died of disease with the median survival after diagnosis of inguinal recurrence of 9 months.
  • In univariate analysis, stage and grade at diagnosis, age and performance status at the recurrent disease, and the extent of residual tumour after resection of groin recurrence were predictors for survival.
  • Groin recurrences from vulvar carcinoma carry a poor prognosis.
  • Multi-modal treatment may result in a palliation of the disease, and a very limited number of patients have long-term survival.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Female. Groin. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832900.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Siow WY, Cheng C: Penile cancer: current challenges. Can J Urol; 2005 Feb;12 Suppl 1:18-23; discussion 97-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Penile cancer remains a formidable challenge in many developing countries because of its high incidence and the advanced disease stage at diagnosis.
  • Penile sparing therapies are proposed as alternative treatment options for select patients with the added advantages of preservation of body image and improved quality of life.
  • The optimal management of lymph node disease remains controversial.
  • The role of the sentinel lymph node biopsy, lymphatic mapping, prophylactic lymphadenectomy and the template for lymph node dissection are discussed.
  • For advanced, metastatic penile cancer, more effective and less toxic chemotherapy is needed.
  • This may be coupled with palliative surgery or radiotherapy for the primary tumor and inguinal disease.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Penile Neoplasms / pathology. Penile Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Developing Countries. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. Singapore / epidemiology. Survival Analysis. Treatment Outcome. Urologic Surgical Procedures, Male / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780160.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 83
  •  go-up   go-down


23. Kaneyasu Y, Okawa T, Yajima M, Saito R, Nakabayashi M, Seshimo A, Kameoka S, Aomi S, Nishikawa T, Sawada T, Mitsuhashi N: Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery. Int J Clin Oncol; 2003 Feb;8(1):60-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and magnetic resonance imaging revealed a large tumor accompanied by lymph node involvement in the left inguinal, multiple pelvic, and paraaortic regions.
  • Neoadjuvant chemotherapy with carboplatin (CBDCA) and 5-fluorouracil (5-FU) was performed, followed by radiotherapy.
  • The tumor responded very well, but still remained in Douglas' pouch after treatment.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Salvage Therapy. Uterine Neoplasms / therapy. Uterus / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Magnetic Resonance Imaging. Metaplasia / diagnosis. Metaplasia / therapy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12601546.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Balogun TM, Omodele FO, Olaiya MA: Primary lymphoma of the testis in remission for more than ten years: a case report. West Afr J Med; 2009 Nov-Dec;28(6):388-90
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is the most common testicular tumour in males between 60 and 80 years old OBJECTIVE: To report a case of primary testicular lymphoma in a young man who has done very well on surgery and chemotherapy.
  • METHODS: The patient a Nigerian male civil servant who was single and aged 31 years presented to us with a history of a progressive painful right scrotal swelling of two years duration and associated painful right groin swelling for one year.
  • A working diagnosis of right hydrocele with differential diagnosis of lymphangioma was made.
  • Right radical inguinal orchidectomy with excision of the right spermatic cord and a regional lymph node was carried out.
  • He was treated with systemic combination chemotherapy and has since been in complete remission for over 10 years.
  • CONCLUSION: Primary testicular lymphoma is a rare and unique neoplasm of the testis and is most commonly seen in men over the age of 60, but should be considered in the differential diagnosis of testicular tumours in younger age groups.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male. Orchiectomy. Remission Induction. Spermatic Cord / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486099.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


25. Fotiou S, Aliki T, Petros Z, Ioanna S, Konstantinos V, Vasiliki M, George C: Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol; 2009 Aug;114(2):178-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All clinical characteristics at initial treatment and relapsing disease, operative and pathologic data of secondary cytoreduction and follow-up information were abstracted from the files and evaluated.
  • RESULTS: Median age at initial treatment was 50 years; 15 patients (71%) had FIGO stage III/IV disease.
  • Following primary surgical and systematic treatment, isolated nodal recurrence was diagnosed after a median DFI of 21 months (range 8-156).
  • Location of nodal disease was pelvic in 4, paraaortic in 8, pelvic plus paraaortic in 4, inguinal in 4 and in the axilla in 1 of the patients.
  • After SCS all patients were treated with chemotherapy (20/21) and/or RT (4/21).
  • Median overall survival after initial diagnosis was 66 months.
  • Combined with post-operative treatment, SCS results in a favorable outcome.
  • [MeSH-major] Lymph Nodes / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Disease-Free Survival. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19450872.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. González-Bugatto F, Añón-Requena MJ, López-Guerrero MA, Báez-Perea JM, Bartha JL, Hervías-Vivancos B: Vulvar leiomyosarcoma in Bartholin's gland area: a case report and literature review. Arch Gynecol Obstet; 2009 Feb;279(2):171-4
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for vulvar leiomyosarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant tumours of the vulvar soft tissue are very uncommon.
  • When localized in the Bartholin's gland area these tumours can be mistaken for benign lesions, leading to a delayed diagnosis.
  • Pathologist report informed of a 6 cm diameter leiomyosarcoma of the vulva with compromised resection margins; extension studies did not suggest any additional lesions and radical hemivulvectomy with ipsilateral inguinal lymphadenectomy was performed.
  • The patient subsequently received radiotherapy and chemotherapy.
  • This is particularly important in order to perform an effective surgical treatment in cases of leiomyosarcoma.
  • [MeSH-major] Bartholin's Glands / pathology. Leiomyosarcoma / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Groin. Humans. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437406.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 14
  •  go-up   go-down


27. Kushner BH, LaQuaglia MP, Kramer K, Cheung NK: Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol; 2004 Jan;26(1):35-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.
  • Neuroblastoma risk stratification is based on stage, age, and biology and prescribes surgery for low-risk disease, moderate-dose chemotherapy for intermediate-risk disease, and maximal therapy (including myeloablative treatment with stem cell transplantation) for high-risk disease.
  • The first recommendations were for maximal therapy, but second opinions were radically different (ie, surgery alone).
  • Ages at diagnosis were 15 to 25 months.
  • All four patients did well without cytotoxic therapy (follow-up: 2 years 10 months plus to 4 years 8 months plus).
  • Biopsies of the latter showed no neuroblastoma and the primary tumor (with regional lymph nodes) was resected, changing stage from 4 to 2B.
  • Patient 4 had a pelvic mass, with unfavorable histopathology, and bilateral inguinal lymph node involvement (stage 3); all soft tissue disease was resected.
  • Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy.
  • [MeSH-major] Health Planning Guidelines. Neuroblastoma / diagnosis. Neuroblastoma / surgery
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707711.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


28. Ohno T, Kato S, Sasaki E, Mizutani K, Tsujii H: Carbon ion radiotherapy for vaginal malignant melanoma: a case report. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1163-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant melanoma of the vagina is a very rare neoplasm and resistant to conventional radiotherapy.
  • On pelvic and imaging examinations, an irregular mass of the posterior vaginal wall sized 7.5 x 5 x 5 cm, an enlarged right inguinal lymph node, and two lung metastases were observed.
  • Histologic diagnosis based on positive immunostaining for HMB-45 was malignant melanoma.
  • She received dacarbazine-based chemotherapy and carbon ion radiotherapy for vaginal and inguinal tumor sites with 57.6 Gy equivalent dose per 16 fractions using five ports.
  • Six months later, she was also given carbon ion radiotherapy for regrowing lung metastasis with 52.8 Gy equivalent dose per four fractions using four ports.
  • She died 19 months after initial treatment due to brain metastases.
  • The primary irradiated tumor disappeared completely 12 months after initial treatment.
  • The vaginal tumor, right inguinal lymph node, and lung tumor treated with carbon ion radiotherapy did not show any evidence of recurrence until her death.
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Carbon Radioisotopes / therapeutic use. Combined Modality Therapy. Dacarbazine / therapeutic use. Fatal Outcome. Female. Humans. Ions / therapeutic use. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17451456.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Carbon Radioisotopes; 0 / Ions; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


29. Micali G, Nasca MR, Innocenzi D, Schwartz RA: Invasive penile carcinoma: a review. Dermatol Surg; 2004 Feb;30(2 Pt 2):311-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To review the pathogenesis and the clinical and histopathologic features of invasive penile carcinomas, with emphasis on current guidelines for their diagnosis and treatment.
  • RESULTS: Penile cancer may develop de novo or in association with underlying factors.
  • The diagnosis should be suspected by clinical findings and must be confirmed histologically.
  • Imaging techniques may be useful for staging and planning therapy.
  • Therapeutic options include excisional surgery, laser destruction, cryosurgery, radiotherapy, immunotherapy, and chemotherapy.
  • CONCLUSIONS: Although there are no current guidelines for the treatment of penile carcinoma, surgical ablation probably represents the best option, as conservative treatments still deserve cautious evaluation because of the relatively small number of treated patients and the lack of good-quality comparative data.
  • Regarding indications for lymph nodal dissection in patients showing no inguinal node enlargement, sentinel node mapping with targeted lymph node dissection is recommended for those with deeply invasive, high-grade tumors, whereas a watchful waiting may be advised for those with superficially invasive, low-grade tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / physiopathology. Carcinoma, Squamous Cell / therapy. Penile Neoplasms / physiopathology. Penile Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Practice Guidelines as Topic. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14871226.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 112
  •  go-up   go-down


30. Agarwal PK, Palmer JS: Testicular and paratesticular neoplasms in prepubertal males. J Urol; 2006 Sep;176(3):875-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We reviewed the current diagnosis, staging and management of testicular and paratesticular neoplasms in prepubertal males.
  • A palpable, nontender mass suggests the diagnosis and prompts scrotal ultrasound and tumor markers.
  • Although treatment for most primary tumors has historically been radical inguinal orchiectomy, most benign tumors can now be managed by testis sparing surgery.
  • The addition of radiation, chemotherapy and/or retroperitoneal lymph node dissection depends on tumor stage and histological type.
  • CONCLUSIONS: Although it is rare in children, any solid scrotal mass in prepubertal males warrants evaluation for possible testicular or paratesticular neoplasm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890643.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


31. Riesz P, Nyirády P, Szucs M, Szendrôi A, Majoros A, Bánfi G, Kiss A, Lotz G, Törzsök P, Kelemen Z, Romics I: [Experiences in treatment and follow up of 50 patients with penile cancer]. Orv Hetil; 2007 Sep 16;148(37):1751-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experiences in treatment and follow up of 50 patients with penile cancer].
  • AIM AND METHOD: Experience with the treatment and attendance of penile cancer is presented by the author.
  • One side inguinal lymph node metastases were found in 11 (22%) and both side in 8 (16%) patients.
  • Seventeen patients (34%) were given chemotherapy after surgical treatment.
  • Mean survival time of all patients was 31,4 (2-114) months.
  • CONCLUSION: Phimosis plays an important role in development of penile cancer, that's surgical treatment does not prevent the higher chance of incidence rate.
  • The disease behaves aggressively, spreading through lymphatic vessels, where in advanced stadium, or in low differentiation cases it is already demonstrable by diagnosis.
  • In the choice of therapy, stadium-oriented principle should be predominant.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Penile Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Verrucous / therapy. Chemotherapy, Adjuvant. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Melanoma / therapy. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827084.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


32. Borchers H, Jakse G: [Lymphadenectomy for penile cancer. Diagnostic and prognostic significance as well as therapeutic benefit]. Urologe A; 2005 Jun;44(6):657-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphadenectomy for penile cancer. Diagnostic and prognostic significance as well as therapeutic benefit].
  • Lymphadenectomy is an essential part of diagnosis and treatment of the squamous cell carcinoma of the penis.
  • In case the inguinal lymphnodes are not palpable a modified lymphadenectomy is indicated.
  • The limits of lymphadenectomy are extended to the radical type of dissection when the frozen section indicates cancer.
  • Inguinal lymphadenectomy is always performed on both sides.
  • Are more than 2 nodes positive the lymphnodes in the true pelvis have to be resected as well.
  • The immediate lymphadenectomy is superior to the delayed lymphadenectomy (palpable nodes during followup) in terms of local recurrence and survival.
  • According to the risk profile patients with palpable inguinal lymphnodes can be initially managed conservatively.
  • Neoadjuvant chemotherapy is reasonable for patients with bulky nodes fixed to the skin or fascia because this improves respectability, freedom from local recurrence and increases survival.
  • Adjuvant chemo- and/or radio-therapy are reserved for extended disease or palliative situations.
  • [MeSH-major] Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Penile Neoplasms / pathology. Penile Neoplasms / surgery. Prostatectomy / methods. Risk Assessment / methods
  • [MeSH-minor] Clinical Trials as Topic. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Practice Guidelines as Topic. Practice Patterns, Physicians'. Preoperative Care / methods. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Urol. 2003 Nov;13(6):467-72 [14560140.001]
  • [Cites] J Urol. 1996 Nov;156(5):1637-42 [8863559.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] Int Urol Nephrol. 2002;34(2):245-50 [12775105.001]
  • [Cites] J Urol. 2002 Jul;168(1):76-80 [12050496.001]
  • [Cites] Arch Ital Urol Androl. 1996 Jun;68(3):169-72 [8767505.001]
  • [Cites] BJU Int. 2001 Sep;88(5):473-83 [11589660.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1089-98 [9426328.001]
  • [Cites] J Urol. 2002 Jan;167(1):89-92; discussion 92-3 [11743282.001]
  • [Cites] Acta Oncol. 1988;27(6b):823-4 [2466471.001]
  • [Cites] J Urol. 1992 Mar;147(3):630-2 [1538445.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1638-9 [12356050.001]
  • [Cites] Urol Int. 1999;62(4):229-33 [10567890.001]
  • [Cites] Urologe A. 2003 Nov;42(11):1466-9 [14624345.001]
  • [Cites] J Urol. 2000 Jan;163(1):100-4 [10604324.001]
  • [Cites] BJU Int. 2000 Oct;86(6):690-3 [11069378.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] J Urol. 2001 May;165(5):1506-9 [11342906.001]
  • [Cites] BJU Int. 2003 Aug;92(3):248-50 [12887477.001]
  • [Cites] Urologe A. 2001 Jul;40(4):308-12 [11490865.001]
  • [Cites] J Urol. 1994 May;151(5):1244-9 [7512656.001]
  • [Cites] J Urol. 2003 Apr;169(4):1349-52 [12629358.001]
  • [Cites] J Urol. 2001 Apr;165(4):1138-42 [11257655.001]
  • [Cites] Urology. 2001 Jul;58(1):65-8 [11445481.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):713-22 [9240637.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):963-8 [11598165.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):525-31 [10668948.001]
  • (PMID = 15891865.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


33. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • 4 months earlier a primary melanoma of the left upper leg had been excised and 2 months later the patient had undergone a left inguinal lymph node dissection revealing 2 metastatic lymph nodes.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • A few weeks later the patient developed macroscopic hematuria.
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed






Advertisement